Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147709 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HTTHSD17B10KDM4EGAA | |
| SCHEMBL20068826 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HTTHSD17B10KDM4EGAA | |
| SCHEMBL25505245 | 0.75 | ALDH1A1 (0.53) | ALDH1A1HTTHSD17B10KDM4EGAA | |
| SCHEMBL20068833 | 0.75 | ALDH1A1 (0.53) | ALDH1A1HTTHSD17B10KDM4EGAA | |
| SCHEMBL20069026 | 0.73 | MAPK1 (0.40) | ALDH1A1HTTHSD17B10MAPK1 | |
| SCHEMBL1332997 | 0.71 | ALDH1A1 (1.00) | ALDH1A1HTTHSD17B10KDM4EGAA | |
| SCHEMBL20158855 | 0.71 | CCNA2 (0.37) | ALDH1A1 | |
| SCHEMBL24263052 | 0.70 | — | — | |
| SCHEMBL21652042 | 0.64 | MAPK1 (0.42) | ALDH1A1HTTHSD17B10MAPK1 | |
| SCHEMBL22857100 | 0.63 | CYP2C9 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | ALDH1A1 2547/4885HTT 3338/4885HSD17B10 4368/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | ALDH1A1 2547/4885HTT 3338/4885HSD17B10 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.